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Abstract: Over the last 110 years, average global life expectancy has more than doubled from 
31 years of age to 65 years of age. This trend is expected to continue, and many of the children 
born after the year 2000 can expect to live to celebrate their hundredth birthday. In the last 
20 years alone, average life expectancy has increased globally by 6 years. 
During the same period, doctors have announced a global epidemic of the most common killers: 
  cardiovascular disease, diabetes, chronic kidney, and chronic obstructive pulmonary disease. One 
of the most important reasons for the more frequent recognition of these diseases is the fact that 
their   diagnostic   criteria have changed and become much more acute during the past few years. 
These changes in diagnostic criteria have made it difficult, or even impossible, to compare the 
  present statistical data regarding these diseases to historical data for the same illnesses. Due to 
this   difficulty, there is no evidence-based comparison of the prevalence of any disease at present 
and in the past. Before announcing a global epidemic, a fair epidemiological comparison should 
be made, based upon the same definitions and using identical diagnostic tools.
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An epidemic (epi- meaning “upon or above” and demos- meaning “people”) occurs when 
new cases of a certain disease, in a given population, and during a given period, substan-
tially exceed what is expected based on recent experience. It may be restricted to one 
locale, or it may be global, in which case it is called a pandemic.1 In the following article, 
the term “epidemic” will be used to refer to an actual increase in disease prevalence.
Life expectancy at birth reflects the overall mortality level of a population. It also 
summarizes the mortality pattern that prevails across different age groups in a given 
year – children, adolescents, adults, and the elderly.
In 1900, the global average life expectancy was 31 years of age, and did not exceed 
50 years in even the richest countries. By the mid-twentieth century, the average 
life expectancy had risen to 48 years. In 2005, the global average lifespan exceeded 
65 years, and in some countries even 80 years. By 2030, the average life expectancy 
in the richest countries will have risen to 85 years. Many of the children born after 
2000 will live to celebrate their hundredth birthday.2
Historically, infectious diseases have long been the leading cause of death and 
  disability. This was particularly evident among children and affected mainly the poorest 
populations in the poorest countries. The constant progress of medicine has led to the 
complete eradication of smallpox, and the virtual eradication of leprosy and polio is 
expected in the next few years. Vaccines against the six killer diseases of childhood 
have been invented. Measles deaths were cut by 48% between 1994 and 2004. The risk 
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of death for children less than 5 years of age is projected to 
fall by over 40% in the next 25 years.
These successes have generated a transition to   societies 
with rapidly increasing numbers of middle-aged and 
elderly. As a result, a different set of diseases has come 
into prominence: cancers, cardiovascular diseases, and 
mental illnesses, all with less impressive treatment results 
in   comparison to infectious diseases.
As life expectancy increases, the major causes of death 
and disability shift from childhood diseases to non-infectious, 
chronic illnesses in adulthood. Chronic diseases cause almost 
35 million (60%) deaths a year. Cardiovascular diseases 
kill as many people as all infectious diseases combined. 
Almost 50% of all chronic disease deaths occur in people 
under 70 years of age. 80% of these deaths are in develop-
ing countries.
In 2005 an estimated 58 million people died worldwide. 
The main causes of death were: cardiovascular diseases 
(29.3%), including ischemic heart disease (12.7%) and 
stroke (9.7%); infectious diseases (23.0%); cancers (12.5%); 
respiratory diseases (6.5%); including chronic obstructive 
pulmonary disease (4.8%); unintentional injuries (6.2%); 
including road traffic accidents (2.1%); diabetes (1.7%).3
The data indicates that in the beginning of the 20th   century, 
cardiovascular disease (CVD) was responsible for less than 
10% of all deaths worldwide, but by 2001 that figure was 
30%. About 80% of the global burden of CVD death occurs 
in developing countries. By 2001, CVD had become the 
leading cause of death in the developing world, as it has 
been in the developed world since the mid-1900s. CVD 
is expected to become the leading cause of death and dis-
ability worldwide by 2020 primarily due to an increase in 
poorer countries. Nearly 50% of all deaths in high-income 
countries, and about 28% of deaths in developing countries, 
are the result of CVD.4
According to current scientific literature, diabetes   mellitus 
(DM) prevalence is increasing in every country in the world. 
Currently, 285 million people, or approximately 6.4% of the 
world’s adult population, live with diabetes. By 2030, this 
number is expected to grow to 439 million.5 Worldwide, 
only half of all people with diabetes are diagnosed.6 Unless 
diabetes prevention, early diagnosis, and treatment are drasti-
cally improved, the world faces a global pandemic. In the 
developing world, type 2 diabetes may account for more than 
95% of all diabetes cases.7
The number of patients with chronic kidney disease 
(CKD), and the subsequent need for renal replacement 
therapy, has reached epidemic proportion and is anticipated 
to rise further. Worldwide, it is estimated that over 1.1   million 
patients with end-stage renal disease currently require 
  maintenance dialysis, and this number is increasing at a rate 
of 7% per year.8
Chronic obstructive pulmonary disease (COPD) is the 
fourth leading cause of death in the world, with approxi-
mately 2.75 million deaths per year, or 4.8% of deaths.3 
COPD is responsible for early mortality, high death rates 
and significant cost to health systems. The projection for 
2020 indicates that COPD will be the third leading cause 
of death worldwide (from sixth in 1990), and fifth lead-
ing cause of years lost through early mortality or handicap 
(twelfth in 1990).9
Keeping all the above in mind, we would like to point 
out that during the last 20 years average life expectancy has 
increased globally by 6 years.1 In the same period,   doctors 
have announced a global epidemic of the most common killers: 
CVD, DM, CKD and COPD. One of the most important 
  reasons for the more frequent recognition of the above diseases 
is the fact that their diagnostic criteria have changed to become 
much more acute during the past few years.
Traditionally, myocardial infarction (MI) was diagnosed 
according to the 1971 WHO criteria based on the clinical syn-
drome, electrocardiography (ECG) changes, and the increase 
of relatively non-specific markers of myocardial damage 
such as creatine kinase (CK).10 The first global definition 
of MI was published in 2000 and was based upon muscle 
and brain (iso-enzyme) of creatine kinase (CK-MB) mass 
and troponin. These criteria are very specific and sensitive 
biological markers of myocardial ischemia.11 The new defini-
tion included clinical data and typical ischemic changes in 
ECG. Another global definition, called a universal definition 
of myocardial infarction, appeared in 2007.12 It was much 
broader in comparison to the definition from 2000, (included 
more clinical situations in which the doctors could establish 
the diagnosis of MI) so it must have expanded the group of 
people diagnosed with MI and ischemic heart disease. The 
use of this universal definition has many social and epide-
miologic implications (increased reporting).
The WHO published the first classification of diabetes in 
1980 and, in modified form, in 1985.13 The second classifica-
tion was widely accepted and used internationally. In 1997, an 
international expert committee released a report with new rec-
ommendations for the classification and diagnosis of diabetes.14 
New diagnostic criteria for diabetes, including a lower cutoff for 
fasting plasma glucose levels (126 mg/dL) (7 mmol/L) instead 
of 140 mg/dL (7.8 mmol/L) must have greatly increased the 
number of people diagnosed with this disease. If the cutoff is 
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further decreased, for instance to 120 mg/dL in 2020, it will 
obviously increase the reporting of diabetes (Figure 1).
In 2002, the National Kidney Foundation defined chronic 
kidney disease (CKD) for the first time as a disorder lasting 3 or 
more months with either kidney damage defined by structural 
or functional abnormalities, or an estimated glomerular filtra-
tion rate (GFR) of less than 60 mL/minute/1.73 m2.15,16 The 
GFR is considered the best measure of overall kidney func-
tion and it physiologically declines with age.17 A GFR level 
below 60 mL/minute/1.73 m2 represents a loss of at least half 
of the adult level of normal kidney function. Because of the 
age-related decline in GFR, the prevalence of chronic kidney 
disease increases with age. Approximately 17% of persons over 
60 years have an estimated GFR (eGFR) of less than 60 mL/
minute/1.73 m2.18 The rise in diagnosis of chronic kidney dis-
ease is multifactorial but associated with the ageing population. 
As technology and medical interventions improve, life spans 
increase, which has an effect on chronic disease populations. 
The incidence of diabetes has reached epidemic proportions 
throughout the world, with an expected doubling in the number 
of patients with type 2 diabetes in the next 25 years. This, in 
turn, will lead to an increased incidence of diabetic nephropa-
thy, with approximately 30% progressing to stage 5 of chronic 
kidney disease. The rise may also be due to the development 
of the above guidelines and simple blood-test-based formulae 
(eg, eGFR) that allow for easier and earlier diagnosis and, 
thus, increased reporting. It is worth remembering that most 
of the formulas for estimating GFR, including the widely used 
methods of Cockroft and Gault, and the Modification of Diet 
in Renal Disease (MDRD),19 contain age.
In 2006, a group of experts published a revised guideline, 
called Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) to update the original version published in 2001.20 
The 2001 GOLD report classified chronic obstructive pulmo-
nary disease (COPD) into 4 levels, defined using spirometry. 
Particular emphasis is placed on forced expiratory volume in 
1 second (FEV1) divided by forced vital capacity (FVC), and on 
the percentage of the predicted value represented by the FEV1 
result. The 2006 report continues to use the same fixed ratio 
of 0.7 for FEV1/FVC (measured after bronchodilator use) to 
define obstruction. The report mentions that this is a recognized 
problem, since the ratio decreases as a normal function of aging; 
using a fixed ratio may lead to overdiagnosis of COPD in older, 
healthy members of the population, similar to CKD.
These changes in diagnostic criteria have made it dif-
ficult, or even impossible, to compare the present statistical 
data regarding these diseases to historical data for the same 
illnesses. Due to this difficulty, there is no evidence-based 
comparison of the prevalence of any disease at present and 
in the past. Before announcing a global epidemic, a fair epi-
demiological comparison should be made, based upon the 
same definitions and using identical diagnostic tools.
On average, people are living longer and diagnostic clas-
sifications are broadening. Therefore, the conviction that 
there is a global epidemic of the most common killers of the 
21st century may be at least partially false, and should be 
explained to society rather than exclaimed.
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Figure 1 Normal data distribution of fasting plasma glucose levels and reporting of 
diabetes depending on the cutoff points.
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